Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

After shares of Novo Nordisk (NVO) fell throughout the last year, the more recent drop may be its last. The company, along with its rival Eli Lilly (LLY), will offer its obesity drug for $499 per ...

Investing.com - 市值17.8亿美元的GoodRx Holdings Inc. (NASDAQ: GDRX )在周二美祖证券的研究报告中维持"中性"评级和5.00美元的目标价。该股近期表现强劲，过去一周上涨超过46%。根据 InvestingPro 分析，该公司的整体财务健康状况被评为"优秀"。

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

Shares in GoodRx ( GDRX) soared more than 37% on Monday and were up a further 3.5% in pre-market trading on Tuesday, after the telemedicine platform operator announced a collaboration with Danish ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

The transaction is led by MCR Investors and its Chairman and CEO, Tyler Morse, with financing from Apollo and Goldman Sachs ...